Dolutegravir Pharmacokinetics Among HIV/TB Coinfected Children Receiving Standard and High-dose Rifampicin

This study examines how dolutegravir — an HIV medication — behaves in the bodies of very young children (aged 4 weeks to under 6 years) who have both HIV and active tuberculosis (TB). The challenge is that rifampicin, a key TB drug, affects how dolutegravir is processed by the body, and this study explores whether a higher rifampicin dose changes this interaction. **You may be eligible if...** - Your child is between 4 weeks and under 6 years old with confirmed HIV infection - Your child has an active TB diagnosis and weighs at least 3 kg - A parent or legal guardian can provide consent **You may NOT be eligible if...** - Your child has severely abnormal lab results (liver enzymes, bilirubin, neutrophil count, platelets, or creatinine) - Your child has suspected TB meningitis or is in acute respiratory distress - Your child is taking other medications that interact with dolutegravir or rifampicin Talk to your doctor to see if this trial is right for you.